SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($2.31), $0.09 worse than the analyst estimate of ($2.22). Revenue for the quarter came in at $1.74 million versus the consensus estimate of $1.68 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.